New Zealand vs Nigeria: Share of the population living with HIV receiving antiretroviral therapy
New Zealand
84.2%
in 2024
Nigeria
83.3%
in 2024
New Zealand rank
41st
Nigeria rank
44th
Share of the population living with HIV receiving antiretroviral therapy over time
- New Zealand
- Nigeria
How they compare
New Zealand currently reports 84.2% against 83.3% in Nigeria, a difference of 0.9%.
The two have swapped places 1 time across 35 shared years of data; in 1990 it was Nigeria ahead.
New Zealand ranks 41st and Nigeria ranks 44th of 149 countries.
New Zealand has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | New Zealand | Nigeria | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 13.4% | 0.0% | 13.4% | New Zealand |
| 2000s | 43.2% | 5.0% | 38.2% | New Zealand |
| 2010s | 64.2% | 35.6% | 28.6% | New Zealand |
| 2020s | 79.2% | 70.8% | 8.4% | New Zealand |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher share of the population living with hiv receiving antiretroviral therapy, New Zealand or Nigeria?
- New Zealand, at 84.2% against 83.3% in Nigeria as of 2024.
- What is the difference in share of the population living with hiv receiving antiretroviral therapy between New Zealand and Nigeria?
- 0.9%, with New Zealand ahead.
- How many years of comparable data are there for New Zealand and Nigeria?
- 35 years are reported by both, from 1990 to 2024.
- How do New Zealand and Nigeria rank globally for share of the population living with hiv receiving antiretroviral therapy?
- New Zealand ranks 41st and Nigeria ranks 44th of 149 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as Share of the population living with HIV receiving antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Percentage of individuals diagnosed with HIV who are currently receiving antiretroviral therapy. This is the central estimate.